Form 4: Amphastar Director Sells 500 Shares via 10b5-1 Plan
Insider Transaction Report
Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for approximately $27.20 per share, executed under a pre-arranged 10b5-1 trading plan.
Summary
- Floyd F. Petersen, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported the sale of 500 shares of common stock.
- The transaction occurred on October 1, 2025.
- The shares were sold at a weighted average price of $27.2048 per share, with individual transaction prices ranging from $26.74 to $27.39.
- This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Petersen on November 26, 2024.
- Following this transaction, Mr. Petersen directly beneficially owns 76,031 shares of Amphastar Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: A routine Form 4 filing reporting a pre-scheduled sale of a small number of shares by a director under a 10b5-1 plan is generally considered neutral, as it does not typically convey new material information about the company's performance or outlook.
Future Outlook
This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitor activities.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The reported sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a pre-arranged schedule for buying or selling company stock to avoid accusations of insider trading. | 11/26/2024 | Demonstrates adherence to SEC regulations for insider trading, providing a legal defense against claims of trading on material non-public information and enhancing transparency regarding insider transactions. |
Stakeholder Impact
- Shareholders: Minimal direct impact due to the small volume of shares sold relative to the company's total outstanding shares. The sale under a 10b5-1 plan indicates a pre-scheduled transaction rather than a reaction to recent events.
Key Dates
| Date | Description |
|---|---|
| 11/26/2024 | Adoption date of the Rule 10b5-1 trading plan by Floyd F. Petersen. |
| 10/01/2025 | Date of the reported transaction (sale of 500 shares of common stock). |
| 10/02/2025 | Date the Form 4 was signed by Eva Wen, by power of attorney. |
Keywords
Amphastar Pharmaceuticals, AMPH, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Floyd F. Petersen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.